COLLEGE PARK, Md. - Federal advisers Thursday said Arpida AG failed to show in clinical trials that its experimental antibiotic iclaprim was safe and effective for treating patients with complicated skin and skin structure infections (cSSSIs). (BioWorld Today) Read More
